Search | Clinical Trials Finder

Conditions: Hemorrhage
Interventions: Kcentra®, Plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 2,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hemorrhage, Thromboembolism
Interventions: Lab tests for plasma levels of apixaban and anti-10a factor; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bleeding Disorder
Interventions: Recombinant von Willebrand Factor; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
Interventions: Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment; Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Not listed
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Traumatic Injury
Interventions: BE1116, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 15 Years and older
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 90
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more

Conditions: Postpartum Hemorrhage, Uterine Atony
Interventions: Uterine Cooling; Procedure
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy, Hepatectomy
Interventions: Not listed
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Mobile, Alabama • Torrance, California • Peoria, Illinois + 3 more

Conditions: Atrial Fibrillation, Cerebrovascular Accident, Death, Sudden
Interventions: Amiodarone, Sotalol; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 28
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • Fresno, California + 25 more

Conditions: Referral and Consultation, Glomerulonephritis, Hematuria, Proteinuria, Kidney Disease
Interventions: Electronic Health Record alert; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 4 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
Interventions: Hemoleven; Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months and older
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stable Angina
Interventions: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel); Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Torrance, California • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Adult Patient Undergoing Major Surgery
Interventions: Masimo hemoglobin-meter, drawing blood sample; Device · Biological
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Orange, California

Conditions: Trauma Injury, Trauma, Critical Illness, Microbiome, Chronic Anemia, Acute Blood Loss Anemia
Interventions: Data and tissue collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Hematochezia
Interventions: Second-generation colon capsule endoscopy system; Device
Lead sponsor: CURE Digestive Diseases Research Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Interventions: Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam; Drug · Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Upper Gastrointestinal Hemorrhage
Interventions: Over-the-scope hemoclipping device, Standard endoscopic treatment; Device · Other
Lead sponsor: CURE Digestive Diseases Research Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Search by objective public record fields.

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Apixaban Discontinuation Prior to Major Surgery

Recombinant vWF Concentrate and ECMO

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage

Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Control of Major Bleeding After Trauma Study

Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients

The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Capsule Endoscopy for Severe Hematochezia

Ketamine for Sedation in Severe Traumatic Brain Injury

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage